Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash & Equivalents (2020 - 2026)

Maxcyte has reported Cash & Equivalents over the past 6 years, most recently at $20.1 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 28.04% to $20.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.1 million through Dec 2025, down 28.04% year-over-year, with the annual reading at $20.1 million for FY2025, 28.04% down from the prior year.
  • Cash & Equivalents was $20.1 million for Q4 2025 at Maxcyte, up from $13.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $239.8 million in Q1 2022 and troughed at $11.1 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $37.5 million (2024), against an average of $49.0 million.
  • The largest YoY upside for Cash & Equivalents was 320.3% in 2023 against a maximum downside of 84.22% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $47.8 million in 2021, then tumbled by 76.84% to $11.1 million in 2022, then surged by 320.3% to $46.5 million in 2023, then crashed by 40.04% to $27.9 million in 2024, then fell by 28.04% to $20.1 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Cash & Equivalents are $20.1 million (Q4 2025), $13.0 million (Q3 2025), and $15.2 million (Q2 2025).